Abstract
Cervical cancer remains a major health problem worldwide, despite advances in screening. For patients with locally advanced stage disease, failure to obtain local-regional control usually results in death. In an effort to improve local-regional tumour control, neoadjuvant and concurrent chemoradiation have been tested. Recently, 5 randomised trials performed by the Gynecologic Oncology Group, Radiation Therapy Oncology Group and the Southwest Oncology Group studying cisplatin-based chemoradiation have demonstrated a significant survival advantage. Three of the trials compared cisplatin-based concurrent chemotherapy and radiation to radiation alone and 2 trials compared cisplatin-based concurrent chemotherapy and radiation to radiation with hydroxyurea. In all trials, cisplatin-based chemotherapy administered concurrently with radiation therapy was the more effective therapy, reducing the risk of death by 30 to 50%. Acute toxicities, principally neutropenia and gastrointestinal, were more common with chemoradiation but were transient and rates of late complications were similar between treatment groups. Based on the results of these 5 randomised trials, the National Cancer Institute released a Clinical Announcement stating that cisplatin-based chemotherapy as used in these trials concurrently with radiation therapy should be the new standard of therapy for high risk early stage and locally advanced stage cervical cancer.
Similar content being viewed by others
References
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33–64
National Cancer Institute. SEER cancer statistics review: 1973–1996. Bethesda (MD): National Cancer Institute, 1999
Jampolis S, Andras J, Fletcher GH. Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 1975; 115: 681–5
Fletcher GH. Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol 1973; 46: 1–12
Byfield JE, Calabro-Jones P, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays. Int J Radiat Oncol Biol Phys 1982; 8: 1923–33
Munro AT. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83–91
Rose PG. Locally advanced cervical carcinoma: the role of chemoradiation. Semin Oncol 1991; 21: 47–53
Hreshyshyn MM, Aron BS, Boronow RC, et al. Hydroxyurea or placebo combined with radiation to treat stages TUB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979; 5: 317–22
Stehman FB, Bundy BN, Thomas G, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993; 11; 1523–8
Thomas G, Dembo A, Beale F, et al. Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: preliminary results of a phase I–II study. Int J Radiat Oncol Biol Phys 1984; 10: 1785–90
Thomas G, Dembo A, Ackerman I, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol 1998; 69: 137–45
Alberts DS, Kronal R, Baker LH, et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 1987; 5: 1791–5
Dionet C, Verrelle P. Curability of mouse L1210 leukemia by combination 5-fluorouracil, cis-diaminedichloroplatnum 11 and low doses of gamma rays. Cancer Res 1984; 44: 652–6
Britten RA, Evans AJ, Allalunis-Turner MJ, et al. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 1996; 34: 367–74
Douple EB, Richmond RC. A review of interactions between platinum coordination complexes and ionizing radiation: implications for cancer therapy. In: Prestayko AW, Crooke ST, Carter SK, editors. Cisplatin current status and new developments. New York (NY): Academic Press Publishers, 1980: 125–47
Choo YC, Choy TK, Wong LC, et al. Potentiation of radiotherapy by cis-dichlorodiammine platinum (II) in advanced cervical carcinoma. Gynecol Oncol 1989; 35: 159–63
Wong LC, Choo YC, Choy D, et al. Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 1989; 35: 159–63
Stehman FB, Bundy BN, Kucera PR, et al. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I–II trial of the gynecologic oncology group. Gynecol Oncol 1997; 66: 262–7
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. NEngl JMed 1999;340: 1137–43
Keys HM, Bundy BM, Stehman FB, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. N Engl J Med 1999; 340: 1154–61
Peters WA III, Liu PY, Barrett RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. J Clin Oncol 2000; 18: 1606–13
Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339–48
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N Engl J Med 1999; 340: 1144–53
National Cancer Institute (NCI). NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival: National Institutes of Health [press release]. Bathesda (MD): NCI Press Office, Feb 2000
Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy: I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67: 2276–85
Potish R, Adcock L, Jones TK, et al. The morbidity and utility of a periaortic radiotherapy in cervical carcinoma. Gynecol Oncol 1983; 15: 1–9
Piver MS, Barlow JJ, Krishnamsetty R. Five-year survival (NED) in patients with biopsy confirmed aortic node metastasis from cervical carcinoma. Am J Obstet Gynecol 1982; 139: 474–8
Varia MA, Stehman FB, Bonomi P, et al. Metastatic carcinoma to paraaortic nodes: results of extended field radiation therapy with hydroxyurea [abstract]. Radiology 1986; 161: 73
Evans LS, Kersh CR, Constable WC, et al. Concomitant 5-fluorouracil, mitomycin-C, and radiotherapy for advanced gynecologic malignancies. Int J Radiat Oncol Biol Phys 1988;15: 901–6
Varia MA, Bundy B, Deppe G, et al. Cervical carcinoma metastatic to the para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy therapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998; 42: 1015–23
Grigsby PW, Lu JD, Mutch DG, et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: phase II Study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998; 41: 817–22
Malfetano JH, Keys H. Aggressive multimodality treatment for cervical cancer with paraaortic lymph node metastases. Gynecol Oncol 1991; 42: 44–7
Corn BW, Hernandez E, Anderson L, et al. Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report. Am J Clin Oncol 1996; 19: 317–21
Muderspach LI, Curtin JP, Roman LD, et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Gynecol Oncol 1997; 65: 336–42
Chen MD, Paley PJ, Potish RA, et al. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 1997; 67: 131–6
Kallman RF, Rapacchietta D, Zaghloul MS. Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems. Int J Radiat Oncol Biol Phys 1991; 20: 227–32
Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials. Gynecol Oncol 2000; 78: 3–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rose, P.G. Chemoradiotherapy. Drugs 60, 1239–1244 (2000). https://doi.org/10.2165/00003495-200060060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200060060-00001